Cardiovascular gene therapy for myocardial infarction

Expert Opinion on Biological Therapy

Volumn 14, Issue 2, 2014, Pages 183-195

  Scimia, Maria C ^a   Gumpert, Anna M ^a   Koch, Walter J ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Efficacy; Gene therapy; Myocardial infarction; Safety

Indexed keywords

ADENYLATE CYCLASE; G PROTEIN COUPLED RECEPTOR KINASE 2; NEUTRALIZING ANTIBODY; PARVALBUMIN; PHOSPHOLAMBAN; S100A1 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANGIOGENESIS; ATHEROSCLEROSIS; BYPASS SURGERY; CARDIOVASCULAR GENE THERAPY; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; GENE EXPRESSION; GENE TRANSFER; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; IN-STENT RESTENOSIS; REGENERATION; REVIEW; SAFETY; STEM CELL TRANSPLANTATION; THERAPY; TROPISM; VEIN GRAFT DISEASE; VIRUS SHEDDING;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; CARDIOVASCULAR SYSTEM; GENE EXPRESSION PROFILING; GENETIC THERAPY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ADRENERGIC; REGENERATION; VENTRICULAR DYSFUNCTION;

EID: 84891920047     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.866085     Document Type: Review

References (137)

1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311(13):819-23
2. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther 1993;60(3):405-30
3. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995;268(5215):1350-3
4. Raake PW, Vinge LE, Gao E, et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 2008;103(4):413-22
5. Koch WJ, Inglese J, Stone WC, Lefkowitz RJ. The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem 1993;268(11):8256-60
6. Akhter SA, Skaer CA, Kypson AP, et al. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA 1997;94(22):12100-5
7. Williams ML, Hata JA, Schroder J, et al. Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. Circulation 2004;109(13):1590-3
8. White DC, Hata JA, Shah AS, et al. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA 2000;97(10):5428-33
9. Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001;103(9):1311-16
10. Raake PW, Schlegel P, Ksienzyk J, et al. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013;34(19):1437-47
11. Brinks H, Boucher M, Gao E, et al. Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro-and anti-apoptotic mechanisms. Circ Res 2010;107(9):1140-9
12. Chen M, Sato PY, Chuprun JK, et al. Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. Circ Res 2013;112(8):1121-34
13. Gao MH, Hammond HK. Unanticipated signaling events associated with cardiac adenylyl cyclase gene transfer. J Mol Cell Cardiol 2011;50(5):751-8
14. Tang T, Gao MH, Hammond HK. Prospects for gene transfer for clinical heart failure. Gene Ther 2012;19(6):606-12
15. Steinberg SF. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res 1999;85(11):1101-11
16. Lai NC, Roth DM, Gao MH, et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 2004;110(3):330-6
17. Lai NC, Roth DM, Gao MH, et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 2000;102(19):2396-401
18. Hulot JS, Senyei G, Hajjar RJ. Sarcoplasmic reticulum and calcium cycling targeting by gene therapy. Gene Ther 2012;19(6):596-9
19. Hadri L, Hajjar RJ. Calcium cycling proteins and their association with heart failure. Clin Pharmacol Ther 2011;90(4):620-4
20. Lipskaia L, Chemaly ER, Hadri L, et al. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther 2010;10(1):29-41
21. Kawase Y, Hajjar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med 2008;5(9):554-65
22. Byrne MJ, Power JM, Preovolos A, et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008;15(23):1550-7
23. Mariani JA, Smolic A, Preovolos A, et al. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail 2011;13(3):247-53
24. Mi YF, Li XY, Tang LJ, et al. Improvement in cardiac function after sarcoplasmic reticulum Ca2+-ATPase gene transfer in a beagle heart failure model. Chin Med J (Engl) 2009;122(12):1423-8
25. Beeri R, Chaput M, Guerrero JL, et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail 2010;3(5):627-34
26. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124(3):304-13
27. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009;15(3):171-81
28. Tsuji T, Del Monte F, Yoshikawa Y, et al. Rescue of Ca2+ overload-induced left ventricular dysfunction by targeted ablation of phospholamban. Am J Physiol Heart Circ Physiol 2009;296(2):H310-17
29. Kaprielian R, del Monte F, Hajjar RJ. Targeting Ca2+ cycling proteins and the action potential in heart failure by gene transfer. Basic Res Cardiol 2002;97(Suppl 1):I136-45
30. Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban- sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999;99(3):313-22
31. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4(7):566-77
32. Pattison JS, Waggoner JR, James J, et al. Phospholamban overexpression in transgenic rabbits. Transgenic Res 2008;17(2):157-70
33. Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002;8(8):864-71
34. Iwanaga Y, Hoshijima M, Gu Y, et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004;113(5):727-36
35. Eizema K, Fechner H, Bezstarosti K, et al. Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1- responsive cardiac promoter. Circulation 2000;101(18):2193-9
36. Kaye DM, Preovolos A, Marshall T, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007;50(3):253-60
37. Suckau L, Fechner H, Chemaly E, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009;119(9):1241-52
38. Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003;299(5611):1410-13
39. Most P, Remppis A, Pleger ST, et al. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007;293(2):R568-77
40. Most P, Pleger ST, Volkers M, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004;114(11):1550-63
41. Pleger ST, Most P, Boucher M, et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007;115(19):2506-15
42. Pleger ST, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011;3(92):92ra64
43. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81(4):1161-72
44. Wahr PA, Michele DE, Metzger JM. Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc Natl Acad Sci USA 1999;96(21):11982-5
45. Coutu P, Bennett CN, Favre EG, et al. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 2004;94(9):1235-41
46. Wang W, Barnabei MS, Asp ML, et al. Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance. Nat Med 2013;19(3):305-12
47. Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart 2011;97(3):181-9
48. Vera Janavel GL, De Lorenzi A, Cortes C, et al. Effect of vascular endothelial growth factor gene transfer on infarct size, left ventricular function and myocardial perfusion in sheep after 2 months of coronary artery occlusion. J Gene Med 2012;14(4):279-87
49. Lazarous DF, Shou M, Stiber JA, et al. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999;44(2):294-302
50. Furlani AP, Kalil RA, Castro I, et al. Effects of therapeutic angiogenesis with plasmid VEGF165 on ventricular function in a canine model of chronic myocardial infarction. Rev Bras Cir Cardiovasc 2009;24(2):143-9
51. Tio RA, Tkebuchava T, Scheuermann TH, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999;10(18):2953-60
52. Laguens R, Cabeza Meckert P, Vera Janavel G, et al. Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer. Gene Ther 2002;9(24):1676-81
53. Heilmann C, von Samson P, Schlegel K, et al. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2. Eur J Cardiothorac Surg 2002;22(6):957-64
54. Heilmann CA, Attmann T, Thiem A, et al. Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia. Eur J Cardiothorac Surg 2003;24(5):785-93
55. Ahmet I, Sawa Y, Yamaguchi T, Matsuda H. Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 2003;75(4):1283-7
56. Rastogi S, Guerrero M, Wang M, et al. Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs. Am J Physiol Heart Circ Physiol 2011;300(4):H1501-9
57. Yang ZJ, Chen B, Sheng Z, et al. Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium-and high-dose groups. Mol Biol Rep 2010;37(4):2075-81
58. Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 2006;13(16):1206-13
59. Penn MS, Mendelsohn FO, Schaer GL, et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 2013;112(5):816-25
60. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-76
61. Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012;485(7400):593-8
62. Song K, Nam YJ, Luo X, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012;485(7400):599-604
63. Jayawardena TM, Egemnazarov B, Finch EA, et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012;110(11):1465-73
64. Greener I, Donahue JK. Gene therapy strategies for cardiac electrical dysfunction. J Mol Cell Cardiol 2011;50(5):759-65
65. Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 2012;125(2):216-25
66. Bikou O, Thomas D, Trappe K, et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 2011;92(2):218-25
67. Amit G, Kikuchi K, Greener ID, et al. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation 2010;121(21):2263-70
68. Watanabe Y, Ito T, Shiomi M. The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits. An animal model for familial hypercholesterolemia. Atherosclerosis 1985;56(1):71-9
69. Scanu AM, Khalil A, Neven L, et al. Genetically determined hypercholesterolemia in a rhesus monkey family due to a deficiency of the LDL receptor. J Lipid Res 1988;29(12):1671-81
70. Ishibashi S, Goldstein JL, Brown MS, et al. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994;93(5):1885-93
71. Shichiri M, Tanaka A, Hirata Y. Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL receptor gene complex. Gene Ther 2003;10(9):827-31
72. El Oakley RM, Al Habib HF. Total arterial coronary revascularization using arterial bypass circle with multiple inflows. Ann Thorac Surg 2007;83(5):1911-12
73. Lopes RD, Williams JB, Mehta RH, et al. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J 2012;164(3):379-86 e1
74. Ohtani K, Usui M, Nakano K, et al. Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther 2004;11(16):1273-82
75. Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med 2013;15(2):65-77
76. Sadelain M. Insertional oncogenesis in gene therapy: how much of a risk? Gene Ther 2004;11(7):569-73
77. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010;11(6):457-60
78. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-19
79. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288(5466):669-72
80. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003;3(7):477-88
81. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110(4):521-9
82. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 2001;20(7):1726-38
83. Baum C, von Kalle C, Staal FJ, et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004;9(1):5-13
84. Gonin P, Buchholz CJ, Pallardy M, Mezzina M. Gene therapy bio-safety: scientific and regulatory issues. Gene Ther 2005;12(Suppl 1):S146-52
85. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103(46):17372-7
86. Kohn DB. Lentiviral vectors ready for prime-time. Nat Biotechnol 2007;25(1):65-6
87. Mortellaro A, Hernandez RJ, Guerrini MM, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood 2006;108(9):2979-88
88. Matyas L, Schulte KL, Dormandy JA, et al. Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Hum Gene Ther 2005;16(10):1202-11
89. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 2008;118(1):9-16
90. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-58
91. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013;122(1):23-36
92. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2011;11(4):321-30
93. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007;7(5):316-24
94. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006;108(1):107-15
95. Arruda VR, Stedman HH, Nichols TC, et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005;105(9):3458-64
96. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999;5(1):56-63
97. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005;5(3):323-31
98. Lowenstein PR, Mandel RJ, Xiong WD, et al. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 2007;7(5):347-60
99. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008;14(5):355-67
100. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199(3):381-90
101. Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther 2011;19(11):2084-91
102. Mingozzi F, Chen Y, Murphy SL, et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther 2012;20(7):1410-16
103. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13(3):R75
104. Mimuro J, Mizukami H, Hishikawa S, et al. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther 2013;21(2):318-23
105. Schenk-Braat EA, van Mierlo MM, Wagemaker G, et al. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007;9(10):910-21
106. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12(3):342-7
107. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98(25):2800-4
108. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100(5):468-74
109. Raake PW, Schlegel P, Ksienzyk J, et al. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013;34(19):1437-47
110. Ishikawa K, Tilemann L, Fish K, Hajjar RJ. Gene delivery methods in cardiac gene therapy. J Gene Med 2011;13(10):566-72
111. Karakikes I, Hadri L, Rapti K, et al. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1. SERCA2a enhances gene transfer in porcine hearts. Mol Ther 2012;20(3):565-71
112. Li H, Li JZ, Helm GA, Pan D. Non-invasive imaging of firefly luciferase reporter gene expression using bioluminescence imaging in human prostate cancer models. Biotechnol Appl Biochem 2007;46(Pt 4):179-84
113. Heim R, Prasher DC, Tsien RY. Wavelength mutations and posttranslational autoxidation of green fluorescent protein. Proc Natl Acad Sci USA 1994;91(26):12501-4
114. Yang M, Baranov E, Moossa AR, et al. Visualizing gene expression by whole-body fluorescence imaging. Proc Natl Acad Sci USA 2000;97(22):12278-82
115. Hoffman RM, Yang M. Whole-body imaging with fluorescent proteins. Nat Protoc 2006;1(3):1429-38
116. Turchin IV, Kamensky VA, Plehanov VI, et al. Fluorescence diffuse tomography for detection of red fluorescent protein expressed tumors in small animals. J Biomed Opt 2008;13(4):041310
117. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003;13(1):195-208
118. Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5-11
119. Sadikot RT, Blackwell TS. Bioluminescence: imaging modality for in vitro and in vivo gene expression. Methods Mol Biol 2008;477:383-94
120. Wu JC, Inubushi M, Sundaresan G, Schelbert HR, Gambhir SS. Optical imaging of cardiac reporter gene expression in living rats. Circulation 2002;105(14):1631-4
121. Wu JC, Chen IY, Wang Y, et al. Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 2004;110(6):685-91
122. Inubushi M, Tamaki N. Positron emission tomography reporter gene imaging in the myocardium: for monitoring of angiogenic gene therapy in ischemic heart disease. J Card Surg 2005;20(6):S20-4
123. Miyagawa M, Anton M, Haubner R, et al. PET of cardiac transgene expression: comparison of 2 approaches based on herpesviral thymidine kinase reporter gene. J Nucl Med 2004;45(11):1917-23
124. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14(1):45-53
125. Bish LT, Sleeper MM, Brainard B, et al. Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther 2008;16(12):1953-9
126. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008;16(6):1073-80
127. Muller OJ, Leuchs B, Pleger ST, et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006;70(1):70-8
128. Geisler A, Jungmann A, Kurreck J, et al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther 2011;18(2):199-209
129. Rengo G, Lymperopoulos A, Zincarelli C, et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009;119(1):89-98
130. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307(4):205-11
131. Choi DJ, Koch WJ, Hunter JJ, Rockman HA. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem 1997;272(27):17223-9
132. Ungerer M, Kessebohm K, Kronsbein K, et al. Activation of beta-adrenergic receptor kinase during myocardial ischemia. Circ Res 1996;79(3):455-60
133. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 1997;99(9):2087-93
134. Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998;95(12):7000-5
135. Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA 2001;98(10):5809-14
136. Rockman HA, Choi DJ, Akhter SA, et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 1998;273(29):18180-4
137. Fan Q, Chen M, Zuo L, et al. Myocardial ablation of G protein-coupled receptor kinase 2 (GRK2) decreases ischemia/reperfusion Injury through an anti-intrinsic apoptotic pathway. PLoS One 2013;8(6):e66234